Researchers say that hormonal birth control for men is as possible and safe as the Pill for women, but the pharmaceutical industry says there's no market
Schering-Plough may have lost billions of dollars in the fourth quarter from an acquisition, but its stock jumped Tuesday as the drugmaker's earnings without charges beat expectations.
As Schering-Plough unveils full-year financial results for 2007 tomorrow, CEO Fred Hassan is likely to be peppered with questions about how he managed a recently released study of embattled cholesterol drug, Vytorin.
Is low cholesterol the pathway to a healthier heart? That's certainly what most medical experts - and their patients - have assumed for the last 30 years or so. But a recently-released study of Merck and Schering-Plough's cholesterol-lowering drug, Vytorin, is giving new voice to medical critics who have groused for decades about the questionable benefit of using medications to lower cholesterol and thereby prevent heart disease.
Government regulators said Friday they are analyzing recent study results regarding cholesterol drug Vytorin, but that it's too early to tell whether it will take any regulatory action.
Schering-Plough's stock almost crawled out of its hole Wednesday after a two-day lashing sparked by the results of a cholesterol drug trial, but the shares fell just before the market's close.
Recently announced safety problems with Eli Lilly & Co.'s prasugrel could mean good news for Schering-Plough and its experimental anti-clotting drug TRA, but it would be years before it could enter the market.
Things aren't as bad as they look at Schering-Plough. The company's shares fell more than 13% yesterday, after its third quarter earnings failed to match Wall Street's expectations. But the company's future, despite the investor sell-off, remains promising.
Drugmaker Schering-Plough is a favorite of analysts and investors these days. It's no wonder: The company's flagship product, the cholesterol-fighting Vytorin, is breaking sales records and faces relatively little risk from cheaper generic versions from rivals.
Researchers say that hormonal birth control for men is as possible and safe as the Pill for women, but the pharmaceutical industry says there's no market
Schering-Plough may have lost billions of dollars in the fourth quarter from an acquisition, but its stock jumped Tuesday as the drugmaker's earnings without charges beat expectations.
As Schering-Plough unveils full-year financial results for 2007 tomorrow, CEO Fred Hassan is likely to be peppered with questions about how he managed a recently released study of embattled cholesterol drug, Vytorin.
Is low cholesterol the pathway to a healthier heart? That's certainly what most medical experts - and their patients - have assumed for the last 30 years or so. But a recently-released study of Merck and Schering-Plough's cholesterol-lowering drug, Vytorin, is giving new voice to medical critics who have groused for decades about the questionable benefit of using medications to lower cholesterol and thereby prevent heart disease.
Government regulators said Friday they are analyzing recent study results regarding cholesterol drug Vytorin, but that it's too early to tell whether it will take any regulatory action.
Schering-Plough's stock almost crawled out of its hole Wednesday after a two-day lashing sparked by the results of a cholesterol drug trial, but the shares fell just before the market's close.
Recently announced safety problems with Eli Lilly & Co.'s prasugrel could mean good news for Schering-Plough and its experimental anti-clotting drug TRA, but it would be years before it could enter the market.
Things aren't as bad as they look at Schering-Plough. The company's shares fell more than 13% yesterday, after its third quarter earnings failed to match Wall Street's expectations. But the company's future, despite the investor sell-off, remains promising.
Drugmaker Schering-Plough is a favorite of analysts and investors these days. It's no wonder: The company's flagship product, the cholesterol-fighting Vytorin, is breaking sales records and faces relatively little risk from cheaper generic versions from rivals.
The Street is bullish on Big Pharma, and experts believe the launch of new, fast-growing drugs fueled earnings for most of the major U.S. drugmakers in the second quarter.
The drugmakers Merck, Schering-Plough and Wyeth all reported strong first-quarter earnings - with Schering and Wyeth trouncing forecasts - but investor reaction was mixed.
Do you enjoy delayed gratification? Consider a career in pharmaceutical research. The wait between a drug's discovery and its approval is usually well over a decade. Often it takes forever: Most ex...
European stocks ended steady Tuesday as drugmakers AstraZeneca and Roche rose on improving prospects for their cancer drugs, but weakness in U.S. shares weighed on the broader market.
In an industry characterized by change, Samuel Isaly has been a rare constant. Since becoming a drug analyst at age 23, after graduating from the London School of Economics, the manager of the $2 ...
Fred Hassan talks like a professional therapist. Not in a cooing, I-feel-your-pain, Oprah sort of way, but with a gentle authority that, no matter how harsh the pronouncement, is still soothing. Sc...
Springtime on the plains of Midland, Texas, is an asthmatic's nightmare. Along with the tumbleweed and dust, there's always too much pollen floating in the wind. Alexis Milmine feels a stirring in ...
How does A.G. Edwards outdistance the S&P 500--and many bigger rivals? Stuart Freeman, the strategist who oversees Edwards' focus list, says the firm's St. Louis location probably helps: "We're les...
Many of the blue-chip growth stocks known as the Nifty Fifty have outpaced the S&P 500, even if you measure from December 1972, when glamour stocks were near peak price/earnings ratios. The stocks ...
For almost two years, investors have quarantined pharmaceuticals and biotechnology stocks. From a peak in early 1992, both groups are down over 30%. The Medical Research Investment Fund has thrived...
It's sweaty-palm season in the stock market. Inflation is rising, corporate earnings are disappointing, and the economy is anemic at best. As a result many investors are quietly shifting into defen...
The page you requested cannot be found. The page you are looking for might have been removed, had its name changed, or is temporarily unavailable.
Please try the following:
• If you typed the page address in the Address bar, make sure that it is spelled correctly.
• Open the edition.cnn.com home page and look for links to the information you want.
• Use the navigation bar above to find the link you are looking for.
• Click the Back button to try another link.
• Enter a term in the search form below to look for information on CNN sites or the Internet.
Video
